ID   SG231
AC   CVCL_0519
SY   PCI:SG231; PCI-SG231; PCI:SG-231
DR   BTO; BTO_0002935
DR   EFO; EFO_0022554
DR   MCCL; MCC:0000417
DR   ATCC; CRL-2126
DR   BioSample; SAMN03472551
DR   cancercelllines; CVCL_0519
DR   Cell_Model_Passport; SIDM01852
DR   DepMap; ACH-001857
DR   Wikidata; Q54953156
RX   CelloPub=CLPUB00275;
RX   PubMed=2176543;
RX   PubMed=27231123;
RX   PubMed=35640676;
RX   PubMed=39026794;
CC   Part of: Biliary tract cancer cell line atlas.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Thr125Pro (c.373A>C); ClinVar=VCV000376666; Zygosity=Unspecified (DepMap=ACH-001857).
CC   Omics: Genomics; Whole exome sequencing.
CC   Discontinued: ATCC; CRL-2126; true.
ST   Source(s): ATCC=CRL-2126; DepMap=ACH-001857
ST   Amelogenin: X
ST   CSF1PO: 10 (ATCC=CRL-2126)
ST   CSF1PO: 10,11 (DepMap=ACH-001857)
ST   D13S317: 9,10
ST   D16S539: 9,14 (DepMap=ACH-001857)
ST   D16S539: 14 (ATCC=CRL-2126)
ST   D18S51: 18
ST   D21S11: 29
ST   D3S1358: 17
ST   D5S818: 12
ST   D7S820: 11
ST   D8S1179: 12,13
ST   FGA: 21,21.2
ST   Penta D: 12,15
ST   Penta E: 10,13
ST   TH01: 8,9
ST   TPOX: 8,11
ST   vWA: 16
DI   NCIt; C35417; Intrahepatic cholangiocarcinoma
DI   ORDO; Orphanet_70567; Cholangiocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   42Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 26
//
RX   CelloPub=CLPUB00275;
RA   Zach S., Birgin E., Ruckert F.;
RT   "Primary cholangiocellular carcinoma cell lines.";
RL   J. Stem Cell Res. Transplant. 2:1013-1013(2015).
//
RX   PubMed=2176543; DOI=10.1002/gcc.2870020408;
RA   Storto P.D., Saidman S.L., Demetris A.J., Letessier E.,
RA   Whiteside T.L., Gollin S.M.;
RT   "Chromosomal breakpoints in cholangiocarcinoma cell lines.";
RL   Genes Chromosomes Cancer 2:300-310(1990).
//
RX   PubMed=27231123; DOI=10.1158/2159-8290.CD-15-1442; PMCID=PMC5458737;
RA   Saha S.K., Gordan J.D., Kleinstiver B.P., Vu P., Najem M.S., Yeo J.-C.,
RA   Shi L., Kato Y., Levin R.S., Webber J.T., Damon L.J., Egan R.K.,
RA   Greninger P., McDermott U., Garnett M.J., Jenkins R.L.,
RA   Rieger-Christ K.M., Sullivan T.B., Hezel A.F., Liss A.S., Mizukami Y.,
RA   Goyal L., Ferrone C.R., Zhu A.X.-X., Joung J.K., Shokat K.M., Benes C.H.,
RA   Bardeesy N.M.;
RT   "Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity
RT   and SRC dependence in intrahepatic cholangiocarcinoma.";
RL   Cancer Discov. 6:727-739(2016).
//
RX   PubMed=35640676; DOI=10.1016/j.ajpath.2022.05.007; PMCID=PMC9472155;
RA   Isidan A., Yenigun A., Soma D., Aksu E., Lopez K., Park Y.,
RA   Cross-Najafi A., Li P., Kundu D., House M.G., Chakraborty S.,
RA   Glaser S., Kennedy L., Francis H., Zhang W.-J., Alpini G.D., Ekser B.;
RT   "Development and characterization of human primary cholangiocarcinoma
RT   cell lines.";
RL   Am. J. Pathol. 192:1200-1217(2022).
//
RX   PubMed=39026794; DOI=10.1101/2024.07.04.601970; PMCID=PMC11257448;
RA   Vijay V., Karisani N., Shi L., Hung Y.-H., Vu P., Kattel P., Kenney L.,
RA   Merritt J., Adil R., Wu Q.-B., Zhen Y.-L., Morris R., Kreuzer J.,
RA   Kathiresan M., Herrera Lopez X.I., Ellis H., Gritti I.G., Lecorgne L.,
RA   Farag I., Popa A., Shen W., Kato H., Xu Q., Balasooriya E.R., Wu M.-J.,
RA   Chaturantabut S., Kelley R.K., Cleary J.M., Lawrence M.S., Root D.E.,
RA   Benes C.H., Deshpande V., Juric D., Sellers W.R., Ferrone C.R., Haas W.,
RA   Vazquez F., Getz G., Bardeesy N.M.;
RT   "Generation of a biliary tract cancer cell line atlas reveals
RT   molecular subtypes and therapeutic targets.";
RL   bioRxiv 2024:07.04.601970-07.04.601970(2024).
//